Palobiofarma and FPWR partner to develop Prader Willi syndrome therapy

2023-05-05
Pharmaceutical Technology
临床1期临床2期
Palobiofarma and FPWR partner to develop Prader Willi syndrome therapy
Preview
来源: Pharmaceutical Technology
Palobiofarma’s PBF-999 has been developed to treat solid tumours such as colon cancer. Credit: Nemeziya / Shutterstock.com.
Spanish biopharmaceutical company Palobiofarma has collaborated with the Foundation for Prader Willi Research (FPWR) to develop its PBF-999 to treat Prader Willi syndrome (PWS).
The company has received a new venture philanthropy award as a convertible loan from FPWR.
Recommended Reports
Palobiofarma and FPWR partner to develop Prader Willi syndrome therapy
Preview
来源: Pharmaceutical Technology
ReportsVon Willebrand Factor (VWF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R... GlobalData
Palobiofarma and FPWR partner to develop Prader Willi syndrome therapy
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS) GlobalData
View all
It intends to utilise the funding from FPWR to partially fund its ongoing Phase II clinical trial of PBF-999, a dual adenosine A2a receptor antagonistadenosine A2a receptor antagonist/phosphodiesterase 10 (PDE-10) inhibitor.
The PDE-10 inhibitor has been developed to treat ‘cold tumours,’ such as colon cancers. It has already been assessed in three clinical trials.
Following observations of an appetite-reducing effect using PBF-999, Palobiofarma designed a clinical trial to assess its efficacy and safety in reducing hyperphagia (excessive hunger) in PWS adults.
Palobiofarma CEO Dr Julio Castro stated: “We are excited to receive this funding from FPWR, which will enable us to continue our mission of developing a treatment to help patients with PWS.”
Led by Dr Assumpta Caixàs, the clinical trial is being conducted at the university hospital Parc Taulí in Sabadell, Spain.
FPWR executive director Susan Hedstrom stated: “Effective treatments for PWS hyperphagia are sorely needed and we are pleased to support Palobiofarma’s efforts on this front.”
In 2018, Palobiofarma commenced recruitment of participants for a Phase I clinical trial of PBF-999 in patients with solid tumours.
Conducted at the Vall D Hebron hospital in Barcelona, Spain, the trial was designed to assess the tolerability and safety of PBF-999.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。